Stockreport

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Nasus Pharma Ltd. Ordinary Shares  (NSRX) 
PDF The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical [Read more]